Acral Lentiginous Melanomas Harbour Intratumor Heterogeneity in BRAF Exon 15, With Mutations Distinct From V600E/V600K

Author(s)

Fernandes, Mariana ^[1] ; Barcelos, Denise ^[1] ; Comodo, Andreia Neves ^[1] ; Guimaraes, Daiane Pereira ^[1] ; Lopes Carapeto, Fernando Cintra ^[1] ; Cardili, Leonardo ^[1] ; Moraes, Lais de Sousa ^[2] ; Cerutti, Janete ^[2] ; Landman, Gilles ^[1]

Affiliation

^[1] Univ Fed Sao Paulo, Dept Pathol, Sao Paulo - Brazil

^[2] Univ Fed Sao Paulo, Dept Morphol & Genet, Sao Paulo - Brazil

• Document type: Journal article
• Source: AMERICAN JOURNAL OF DERMATOPATHOLOGY; v. 41, n. 10, p. 733-740, OCT 2019.
• Web of Science Citations: 1

Abstract

The choice of appropriate therapeutic strategies may be influenced by intratumor heterogeneity and makes cancer treatment considerably more challenging. We aimed to evaluate the heterogeneity of BRAF exon 15 mutations in different areas of acral lentiginous melanoma (ALM). The entire exon 15 was sequenced in 4 different areas of paraffin-embedded samples from 26 patients with ALM. A total of 26 of 49 cases of >= 1 mm in depth of ALM identified by clinical, anatomical, and pathological data fulfilled the inclusion and exclusion criteria for this study. Tumors had a mean Breslow depth of 7.2 mm and an average mitotic index of 3 mitosis/ mm(2). Mutations distinct from the common V600E and V600K were detected in 31%, and intratumor heterogeneity was observed in 31% of samples. Interestingly, 63.5% of all mutations had been previously associated with cancer. Most (62.5%) of the missense BRAF exon 15 mutations found in the ALM samples examined here were deemed ``detrimental{''} for protein function according to at least 2 functional prediction programs, and 3 mutations (37.5%) were predicted to be ``neutral,{''} with no effect on protein function. BRAF exon 15 mutations were detected frequently in ALM and displayed heterogeneity, a finding to be further investigated. (AU)

• FAPESP's process: 12/11408-8 - Evaluation of BRAF (7q34), MAP2K1 (15q22.1-q22.33) and MAP2K2 (19p13.3) in acral lentiginous melanoma
• Grantee: Gilles Landman
• Support Opportunities: Regular Research Grants